zurück

Sotrovimab (COVID-19 patients aged ≥ 12 years)


Subject:

  • Active Substance: Sotrovimab
  • Name: Xevudy®
  • Therapeutic area: Coronavirus disease 2019 (COVID-19)
  • Pharmaceutical company: GlaxoSmithKline GmbH & Co. KG


Time table:

  • Start: 15.05.2022
  • Final decision by G-BA: 03.11.2022


Final decision:

  1. Adult patients with COVID-19 disease who do not require supplemental oxygen therapy and who are at increased risk for a severe course of COVID-19 in the case of infection with an infection with a viral variant against which sotrovimab has significantly reduced or insufficient efficacy: No additional benefit proved
  2. Adult patients with COVID-19 disease who do not require supplemental oxygen therapy and who are at increased risk for a severe course of COVID-19 in the case of infection with an infection with a viral variant against which sotrovimab has sufficient efficacy: Hint for a considerable additional benefit
  3. Adolescents from 12 to < 18 years of age with at least 40 kg body weight with COVID-19 disease who do not require supplemental oxygen therapy and are at increased risk for a severe course of COVID-19: No additional benefit proved